Dissolution and bioavailability of lercanidipine-hydroxypropylmethyl cellulose nanoparticles with surfactant

International Journal of Biological Macromolecules

Volumn 72, Issue , 2015, Pages 218-222

  Ha, Eun Sol ^a   Choo, Gwang Ho ^a   Baek, In hwan ^b   Kim, Jung Soo ^c   Cho, Wonkyung ^c,d   Jung, Young Suk ^a   Jin, Su Eon ^d   Hwang, Sung Joo ^d   Kim, Min Soo ^a  

^a Pusan National University   (South Korea)

^b Kyungsung University   (South Korea)

^c Chungnam National University   (South Korea)

^d Yonsei University   (South Korea)

Author keywords

Bioavailability; Lercanidipine; Nanoparticle

Indexed keywords

GELUCIRE; HYDROXYPROPYLMETHYLCELLULOSE; LERCANIDIPINE; MACROGOL; NANOPARTICLE; POLOXAMER; SURFACTANT; ALPHA TOCOPHEROL; DIHYDROPYRIDINE DERIVATIVE; GELUCIRE 44-14; MACROGOL DERIVATIVE; TOCOFERSOLAN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG SOLUBILITY; ELECTROSPRAY; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MELTING POINT; NONHUMAN; PARTICLE SIZE; RAT; SUPERCRITICAL FLUID; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY DIFFRACTION; BIOAVAILABILITY; CHEMISTRY; DRUG FORMULATION; HUMAN; ORAL DRUG ADMINISTRATION; SOLUBILITY;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; DIHYDROPYRIDINES; DRUG COMPOUNDING; HUMANS; HYPROMELLOSE DERIVATIVES; NANOPARTICLES; PARTICLE SIZE; POLOXAMER; POLYETHYLENE GLYCOLS; SOLUBILITY; VITAMIN E;

EID: 84907728553     PISSN: 01418130     EISSN: 18790003     Source Type: Journal    
DOI: 10.1016/j.ijbiomac.2014.08.017     Document Type: Article

References (26)

1. Baek I.H., Kim J.S., Ha E.S., Choo G.H., Cho W., Hwang S.J., Kim M.S. Int. J. Biol. Macromol. 2014, 69:222-228.
2. Yoon G., Park J.W., Yoon I.-S. J. Pharm. Invest. 2013, 43:353-362.
3. Choi J.H., Lee K., Hong S., Lee S.K., Oh Y.-K., Choi S.K., Choi H.-G. J. Pharm. Invest. 2013, 43:507-512.
4. Reverchon E., Adami R., Cardea S., Porta G.D. J. Supercrit. Fluids 2009, 47:484-492.
5. Yeo S.-D., Kiran E. J. Supercrit. Fluids 2005, 34:287-308.
6. Paudel A., Worku Z.A., Meeus J., Guns S., Van den Mooter G. Int. J. Pharm. 2013, 453:253-284.
7. Pasquali I., Bettini R. Int. J. Pharm. 2008, 364:176-187.
8. Johnston K.P., da Rocha S.R.P. J. Supercrit. Fluids 2009, 47:523-530.
9. Kim M.S., Lee S., Park J.S., Woo J.S., Hwang S.J. Powder Technol. 2007, 177:64-70.
10. Kim M.S., Jin S.J., Kim J.S., Park H.J., Song H.S., Neubert R.H., Hwang S.J. Euro. J. Pharm. Biopharm. 2008, 69:454-465.
11. Cha K.H., Cho K.J., Kim M.S., Kim J.S., Park H.J., Park J., Cho W., Park J.S., Hwang S.J. Int. J. Nanomed. 2012, 7:5565-5575.
12. Yasuji T., Takeuchi H., Kawashima Y. Adv. Drug Delivery Rev. 2008, 60:388-398.
13. Cocero M.J., Martín Á., Mattea F., Varona S. J. Supercrit. Fluids 2009, 47:546-555.
14. Lee S., Nam K., Kim M.S., Jun S.W., Park J.S., Woo J.S., Hwang S.J. Arch. Pharm. Res. 2005, 28:866-874.
15. Adeli E. J. Supercrit. Fluids 2014, 87:9-21.
16. Kim M.S., Kim J.S., Cho W., Park H.J., Hwang S.J. Int. J. Biol. Macromol. 2013, 59:138-142.
17. Kim M.S., Kim J.S., Park H.J., Cho W.K., Cha K.H., Hwang S.J. Int. J. Nanomed. 2011, 6:2997-3009.
18. Kim M.S. Int. J. Nanomed. 2013, 8:2029-2039.
19. McClellan K.J., Jarvis B. Drugs 2000, 60:1123-1140.
20. Barchielli M., Dolfini E., Farina P., Leoni B., Targa G., Vinaccia V., Tajana A. J. Cardiovasc. Pharmacol. 1997, 29:S1-S15.
21. Chen K., Zhang J., Liu S., Zhang D., Teng Y., Wei C., Wang B., Liu X., Yuan G., Zhang R., Zhao W., Guo R. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2012, 899:1-7.
22. Kim M.S., Kim J.S., Hwang S.J. Chem. Pharm. Bull. 2010, 58:230-233.
23. Khan K.A., Rhodes C.T. Pharm. Act. Helv. 1972, 47:594-607.
24. Dressman J.B., Amidon G.L., Reppas C., Shah V.P. Pharm. Res. 1998, 15:11-22.
25. Baek I.H., Kim J.S., Ha E.S., Choo G.H., Cho W., Hwang S.J., Kim M.S. Int. J. Biol. Macromol. 2014, 67:53-57.
26. Barakat A., Shegokar R., Dittgen M., Müller R.H. J. Pharm. Invest. 2013, 43:431-451.